{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:56:38Z","timestamp":1790873798933,"version":"4.1.0"},"reference-count":41,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["40-41200-98-9331"],"award-info":[{"award-number":["40-41200-98-9331"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018286","name":"Dutch Arthritis Society","doi-asserted-by":"publisher","award":["LLP28"],"award-info":[{"award-number":["LLP28"]}],"id":[{"id":"10.13039\/100018286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,8,21]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In rheumatoid arthritis (RA), immunosuppressive therapies may achieve symptomatic relief, but do not induce long-term, drug-free remission. Meanwhile, the lifelong use of immunosuppressive drugs confers increased risk for malignancy and infections. As such, there is an unmet need for novel treatments that selectively target the pathogenic immune response in RA by inducing tolerance to autoantigens. Autologous cell therapy using antigen-loaded tolerogenic dendritic cells (tolDCs) aims to reinstate autoantigen-specific immunological tolerance in RA and could potentially meet this need.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      We report here the design of the phase I\/II, investigator-initiated, open-label, dose-escalation trial TOLERANT. In this study, we will evaluate the intranodal administration of tolDCs in patients with RA that are in remission under immunosuppressive therapy. The tolDCs in this trial are loaded with the heat shock protein 70-derived peptide mB29a, which is an effective surrogate autoantigen in animal models of arthritis. Within this study, three dose-escalation cohorts (two intranodal injections of 5\u00d710\n                      <jats:sup>6<\/jats:sup>\n                      , 10\u00d710\n                      <jats:sup>6<\/jats:sup>\n                      and 15\u00d710\n                      <jats:sup>6<\/jats:sup>\n                      tolDCs), each consisting of three patients, are evaluated to identify the highest safe dose (recommended dose), and an extension cohort of nine patients will be treated with the recommended dose. The (co-)primary endpoints of this study are safety and feasibility, which we assess by the number of AEs and the successful production of tolDCs. The secondary endpoints include the immunological effects of the treatment, which we assess with a variety of high-dimensional and antigen-specific immunological assays. Clinical effects are exploratory outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval for this study has been obtained from the Netherlands Central Committee on Research Involving Human Subjects. The outcomes of the trial will be disseminated through publications in open-access, peer-reviewed scientific journals, scientific conferences and to patient associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration numbers<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05251870\">NCT05251870<\/jats:ext-link>\n                      ; 2019-003620-20 (EudraCT); NL71296.000.20 (CCMO register).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-078231","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T14:45:32Z","timestamp":1726152332000},"page":"e078231","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Design of TOLERANT: phase I\/II safety assessment of intranodal administration of HSP70\/mB29a self-peptide antigen-loaded autologous tolerogenic dendritic cells in patients with rheumatoid arthritis"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05251870","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1969-6146","authenticated-orcid":false,"given":"Arie Jan","family":"Stoppelenburg","sequence":"first","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands"},{"name":"Department of Biomolecular Health Sciences, Utrecht University Faculty of Veterinary Medicine, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerty","family":"Schreibelt","sequence":"additional","affiliation":[{"name":"Department of Medical BioSciences, Radboud University Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouke","family":"Koeneman","sequence":"additional","affiliation":[{"name":"Department of Medical BioSciences, Radboud University Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paco","family":"Welsing","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evert-Jan","family":"Breman","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laureen","family":"Lammers","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"de Goede","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjitske","family":"Duiveman-de Boer","sequence":"additional","affiliation":[{"name":"Department of Medical BioSciences, Radboud University Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"van Eden","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Health Sciences, Utrecht University Faculty of Veterinary Medicine, Utrecht, The Netherlands"},{"name":"Trajectum Pharma B.V, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Leufkens","sequence":"additional","affiliation":[{"name":"Trajectum Pharma B.V, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I Jolanda M","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Medical BioSciences, Radboud University Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Broere","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Health Sciences, Utrecht University Faculty of Veterinary Medicine, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M","family":"van Laar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"2025121602515118000_14.9.e078231.1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0407704101"},{"key":"2025121602515118000_14.9.e078231.2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041717"},{"key":"2025121602515118000_14.9.e078231.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0041-4"},{"key":"2025121602515118000_14.9.e078231.4","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.immuni.2018.12.001","article-title":"The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases","volume":"49","author":"Roncarolo","year":"2018","journal-title":"Immunity"},{"key":"2025121602515118000_14.9.e078231.5","doi-asserted-by":"crossref","DOI":"10.1186\/ar3848","article-title":"T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles","volume":"14","author":"Law","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2025121602515118000_14.9.e078231.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.25064"},{"key":"2025121602515118000_14.9.e078231.7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/imm.12811","article-title":"Targeting of tolerogenic dendritic cells towards heat-shock proteins: a novel therapeutic strategy for autoimmune diseases?","volume":"153","author":"Jansen","year":"2018","journal-title":"Immunology"},{"key":"2025121602515118000_14.9.e078231.8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI2465"},{"key":"2025121602515118000_14.9.e078231.9","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-019-2128-4","article-title":"Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis","volume":"17","author":"Spiering","year":"2019","journal-title":"J Transl Med"},{"key":"2025121602515118000_14.9.e078231.10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s12192-013-0484-1","article-title":"T cell recognition of naturally presented epitopes of self-heat shock protein 70","volume":"19","author":"de Jong","year":"2014","journal-title":"Cell Stress Chaperones"},{"key":"2025121602515118000_14.9.e078231.11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117801"},{"key":"2025121602515118000_14.9.e078231.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780391108"},{"key":"2025121602515118000_14.9.e078231.13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12192-018-0951-9","article-title":"Autoantibodies to heat shock proteins 60, 70, and 90 in patients with rheumatoid arthritis","volume":"24","author":"Mantej","year":"2019","journal-title":"Cell Stress Chaperones"},{"key":"2025121602515118000_14.9.e078231.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806310105"},{"key":"2025121602515118000_14.9.e078231.15","doi-asserted-by":"crossref","DOI":"10.1038\/nri2873-c1","article-title":"Heat shock proteins are no DAMPs, rather \u201cDAMPERs\u201d","volume":"11","author":"Broere","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"2025121602515118000_14.9.e078231.16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1206803109"},{"key":"2025121602515118000_14.9.e078231.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128373","article-title":"In vivo induction of functionally suppressive induced regulatory T cells from CD4+CD25- T cells using an Hsp70 peptide","volume":"10","author":"van Herwijnen","year":"2015","journal-title":"PLoS ONE"},{"key":"2025121602515118000_14.9.e078231.18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.39444","article-title":"An arthritis-suppressive and treg cell-inducing CD4+ T cell epitope is functional in the context of HLA-restricted T cell responses","volume":"68","author":"de Wolf","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025121602515118000_14.9.e078231.19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501190102"},{"key":"2025121602515118000_14.9.e078231.20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02068","article-title":"Matured tolerogenic dendritic cells effectively inhibit autoantigen specific CD4+ T cells in a murine arthritis model","volume":"10","author":"Jansen","year":"2019","journal-title":"Front Immunol"},{"key":"2025121602515118000_14.9.e078231.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.27756"},{"key":"2025121602515118000_14.9.e078231.22","doi-asserted-by":"publisher","DOI":"10.1007\/s12192-012-0397-4"},{"key":"2025121602515118000_14.9.e078231.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126383"},{"key":"2025121602515118000_14.9.e078231.24","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0608374"},{"key":"2025121602515118000_14.9.e078231.25","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.2300","article-title":"Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies","volume":"4","author":"Lord","year":"2016","journal-title":"PeerJ"},{"key":"2025121602515118000_14.9.e078231.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208456"},{"key":"2025121602515118000_14.9.e078231.27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci Transl Med"},{"key":"2025121602515118000_14.9.e078231.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820039116"},{"key":"2025121602515118000_14.9.e078231.29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S2213-8587(20)30104-2","article-title":"Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide-for type 1 diabetes","volume":"8","author":"Nikolic","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025121602515118000_14.9.e078231.30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1054968","article-title":"Tolerogenic dendritic cells pulsed with islet antigen induce long-term reduction in T-cell autoreactivity in type 1 diabetes patients","volume":"13","author":"Nikolic","year":"2022","journal-title":"Front Immunol"},{"key":"2025121602515118000_14.9.e078231.31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1075813","article-title":"The emerging role of regulatory cell-based therapy in autoimmune disease","volume":"13","author":"Ghobadinezhad","year":"2022","journal-title":"Front Immunol"},{"key":"2025121602515118000_14.9.e078231.32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.it.2020.11.001","article-title":"Tolerogenic dendritic cells in autoimmunity and inflammatory diseases","volume":"42","author":"Morante-Palacios","year":"2021","journal-title":"Trends Immunol"},{"key":"2025121602515118000_14.9.e078231.33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030309","article-title":"Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration","volume":"9","author":"Willekens","year":"2019","journal-title":"BMJ Open"},{"key":"2025121602515118000_14.9.e078231.34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2729"},{"key":"2025121602515118000_14.9.e078231.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110420","article-title":"JAK1 signaling in dendritic cells promotes peripheral tolerance in autoimmunity through PD-L1-mediated regulatory T cell induction","volume":"38","author":"Vogel","year":"2022","journal-title":"Cell Rep"},{"key":"2025121602515118000_14.9.e078231.36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20051142","article-title":"Context-dependent effect of glucocorticoids on the proliferation, differentiation, and apoptosis of regulatory T cells: a review of the empirical evidence and clinical applications","volume":"20","author":"Cari","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025121602515118000_14.9.e078231.37","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1019197","article-title":"Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients","volume":"4","author":"Bol","year":"2015","journal-title":"Oncoimmunology"},{"key":"2025121602515118000_14.9.e078231.38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci Transl Med"},{"key":"2025121602515118000_14.9.e078231.39","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/acr.20620","article-title":"Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL)","volume":"63","author":"Maska","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025121602515118000_14.9.e078231.40","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025121602515118000_14.9.e078231.41","unstructured":"Young Bin Joo J-E , Choi C-B , Choi J , et al . Phase 1 Study of Immunotherapy Using Autoantigen-Loaded Dendritic Cells in Patients with Anti-Citrullinated Peptide Antigen Positive Rheumatoid Arthritis. 2014 ACR\/ARHP Annual Meeting. 2014."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-078231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:52:02Z","timestamp":1765882322000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-078231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,12]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/bmjopen-2023-078231"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-078231","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}